Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision Next revision | ||
blog:bpaddock:chronic_pain_suicidal_behavior_and_ideation_and_antiepileptic_drugs [2017/03/27 19:40] bpaddock Added reference to the original Cell paper. | blog:bpaddock:chronic_pain_suicidal_behavior_and_ideation_and_antiepileptic_drugs [2017/07/23 12:33] bpaddock 2016 study update | ||
---|---|---|---|
Line 17: | Line 17: | ||
Çagla Eroglu, Nicola J. Allen, Michael W. Susman, Nancy A. O' | Çagla Eroglu, Nicola J. Allen, Michael W. Susman, Nancy A. O' | ||
- | Synapses are asymmetric cellular adhesions that are critical for nervous system development and function, but the mechanisms that induce their formation are not well understood. We have previously identified thrombospondin as an astrocyte-secreted protein that promotes central nervous system (CNS) synaptogenesis. Here, we identify the neuronal thrombospondin receptor involved in CNS synapse formation as α2δ-1, the receptor for the anti-epileptic and analgesic drug gabapentin. We show that the VWF-A domain of α2δ-1 interacts with the epidermal growth factor-like repeats common to all thrombospondins. | + | Synapses are asymmetric cellular adhesions that are critical for nervous system development and function, but the mechanisms that induce their formation are not well understood. We have previously identified thrombospondin as an astrocyte-secreted protein that promotes central nervous system (CNS) synaptogenesis. Here, we identify the neuronal thrombospondin receptor involved in CNS synapse formation as α2δ-1, the receptor for the anti-epileptic and analgesic drug gabapentin. We show that the VWF-A domain of α2δ-1 interacts with the epidermal growth factor-like repeats common to all thrombospondins. |
+ | </ | ||
+ | |||
+ | ====== Interference with neuronal development ====== | ||
+ | |||
+ | This class of medication interferes with neuronal development at //any// age. | ||
+ | Study from 2016 on prenatal development. | ||
+ | |||
+ | // | ||
+ | |||
+ | < | ||
+ | ABSTRACT | ||
+ | |||
+ | Objective: To investigate pregnancy outcomes following maternal use of pregabalin. | ||
+ | |||
+ | Methods: This multicenter, | ||
+ | |||
+ | Results: Data were collected from 164 exposed pregnancies and 656 controls. A significantly higher major birth defect rate in the pregabalin group was observed after exclusion of chromosomal aberration syndromes, and when cases with exposure during first trimester of pregnancy were analyzed separately (7/116 [6.0%] vs 12/580 [2.1%]; odds ratio 3.0, 95% confidence interval 1.2–7.9, p = 0.03). The rate of live births was lower in the pregabalin group (71.9% vs 85.2%, p < 0.001), primarily due to a higher rate of both elective (9.8% vs 5.0%, p = 0.02) and medically indicated (5.5% vs 1.8%, p = 0.008) pregnancy terminations. In the Cox proportional cause specific hazards model, pregabalin exposure was not associated with a significantly higher risk of spontaneous abortion. | ||
+ | |||
+ | Conclusions: | ||
</ | </ | ||